A random-effects model (c2-based Q-statistic test: q = 1065.86; P < 0.001; I2 = 93.4%) revealed that the total occurrence of all-grade hypertensive occasions in cancer patients treated with VEGFR-TKIs was 4.4% (3.7-5.0%, 95% CI, Supplementary Table 4 and Figure S2). This evidence concerns the gene KDR and cancer.